Evaluation of ATN_{PD} framework and biofluid markers to predict cognitive decline in early Parkinson's disease

Katheryn A.Q. Cousins, PhD¹, David J. Irwin, MD¹, Thomas F. Tropea, DO¹, Emma
Rhodes, PhD¹, Jeffrey S. Phillips, PhD¹, Alice S. Chen-Plotkin, MD¹, Michael C. Brumm, MS², Christopher S. Coffey, PhD², Ju Hee Kang, PhD³, Tanya Simuni, MD⁴, Tatiana
Foroud, PhD⁵, Arthur W. Toga, PhD⁶, Caroline M. Tanner, MD PhD⁷, Karl Kieburtz, MD, MPH⁸, Brit Mollenhauer, MD⁹, Douglas R. Galasko, MD¹⁰, Samantha Hutten, PhD¹¹, Daniel Weintraub, MD^{1,12,13}, Andrew Siderowf, MD¹, Kenneth Marek, MD¹⁴, Gwendlyn Kollmorgen¹⁵, Kathleen L. Poston, MD, MS¹⁶, Leslie M. Shaw, PhD¹⁷, The Parkinson's Progression Marker Initiative

January 07, 2023

¹Department of Neurology, Perelman School of Medicine, University of Pennsylvania. ²Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA. ³Department of Pharmacology & Clinical Pharmacology, Inha University, Incheon, South Korea. ⁴Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. ⁵Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA. ⁶Laboratory of Neuro Imaging, University of Southern California, Los Angeles, CA, USA; ⁷Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA. ⁸Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. ⁹Department of Neurology, University Medical Center, Göttingen, Paracelsus-Elena-Klinik, Kassel and Scientific Employee with an Honorary Contract at German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.¹⁰Department of Neurology, University of California San Diego, San Diego, CA, USA.¹¹The Michael J. Fox Foundation, New York, NY, USA. ¹²Department of Psychiatry Perelman, School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. ¹³Michael J. Crescenz VA Medical Center, Parkinson's Disease Research, Education, and Clinical Center, Philadelphia, PA, USA. ¹⁴Institute for Neurodegenerative Disorders, New Haven, CT, USA. ¹⁵ Roche Diagnostics GmbH, Penzberg, Germany.¹⁶Department of Neurology, Stanford University, Palo Alto, CA, USA. ¹⁷Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania.

Correspondence should be addressed to Katheryn Cousins Department of Neurology Richards Medical Research Laboratories, Suite 600B 3700 Hamilton Walk Philadelphia, PA 19104 *katheryn.cousins@pennmedicine.upenn.edu*

Study Type: Observational study

Running head: Modified ATN in Parkinson's disease

Title length: 108 characters/140 characters Running head length: 35/50 characters Abstract: 347/350 words Body of the manuscript: 3989/4500 words Number of figures: 5 (5 color) Number of tables: 2

Abstract

Background and Objectives: In Parkinson's disease (PD), Alzheimer's disease (AD) copathology is common and clinically relevant. However, the longitudinal progression of AD cerebrospinal fluid (CSF) biomarkers – β -amyloid 1-42 (A β_{42}), phosphorylated tau 181 (p-tau₁₈₁) and total tau (t-tau) – in PD is poorly understood, and may be distinct from clinical AD. Moreover, it is unclear if CSF p-tau₁₈₁ and serum neurofilament light (NfL) have added prognostic utility in PD, when combined with CSF A β_{42} . First, we describe longitudinal trajectories of biofluid markers in PD. Second, we modified the AD β amyloid/tau/neurodegeneration (ATN) framework for application in PD (ATN_{PD}) using CSF A β_{42} (A), p-tau₁₈₁ (T), and serum NfL (N), and tested ATN_{PD} prediction of longitudinal cognitive decline in PD.

Methods: Participants were selected from the Parkinson's Progression Markers Initiative (PPMI) cohort, clinically-diagnosed with sporadic PD or as normal Controls, and followed annually for 5 years. Linear mixed effects models (LMEM) tested the interaction of diagnosis with longitudinal trajectories of analytes (log-transformed, FDR-corrected). In PD, LMEMs tested how baseline ATN_{PD} status (AD [A+T+N±] *vs.* not) predicted clinical outcomes, including Montreal Cognitive Assessment (MoCA; rank-transformed, FDR-corrected).

Results: Participants were 364 PD and 168 Controls, with comparable baseline mean (±SD) age (PD=62±10; Control=61±11]; Mann-Whitney-Wilcoxon: p=0.40) and gender distribution (PD=231 males [63%]; Control=107 males [64%]; chi-square: p=1.0). PD had overall lower CSF p-tau₁₈₁ (β =-0.16, 95%CI=-0.23 – -0.092, p=2.2e-05) and t-tau than Controls (β =-0.13, 95%CI=-0.19 – -0.065, p=4.0e-04), but not A β_{42} (p=0.061) or NfL (p=0.32). Over time, PD had greater increases in serum NfL than Controls (β =0.035, 95%CI=0.022 – 0.048, p=9.8e-07); PD slopes did not differ from controls for CSF A β_{42} (p=0.18), p-tau₁₈₁ (p=1.0) or t-tau (p=0.96). Using ATN_{PD}, PD classified as A+T+N± (n=32; 9%) had consistently worse cognitive decline, including on global MoCA (β =-73, 95%CI=-110 – -37, p=0.00077), than all other ATN_{PD} statuses including A+ alone (A+T-N-; n=75; 21%).

Discussion: In early PD, CSF p-tau₁₈₁ and t-tau were low compared to Controls and did not increase over 5 year follow-up. Even so, classification using modified ATN_{PD} (incorporating CSF p-tau₁₈₁ with CSF A β_{42} and serum NfL) may identify biologically-relevant subgroups of PD to improve prediction of cognitive decline in early PD.

1. Introduction

Parkinson's disease (PD) is a progressive movement disorder associated with underlying α -synuclein positive Lewy bodies¹. Clinically-relevant levels of Alzheimer's disease (AD) pathology are common in Lewy body disease (LBD), with roughly 40% having sufficient β -amyloid plaques and tau neurofibrillary tangles for a secondary neuropathological diagnosis of intermediate-to-high AD neuropathologic change (ADNC)^{2,3}. Moreover, AD co-pathology in PD may contribute to more severe episodic memory and language impairments, as well as worse postural instability and shorter survival³⁻⁶. AD biomarkers may prove important to prognosticate clinical outcomes in PD. It is therefore important to track when AD pathology might arise in PD, yet there have been limited studies of AD biomarker trajectories in early PD.

In addition to poorly understood biomarker dynamics in PD, there is no established framework for AD biomarker classification in PD. The ATN framework was developed to diagnose individuals along a continuum of AD^7 , and cerebrospinal fluid (CSF) biomarkers can determine likely presence (+) or absence (-) of AD pathological hallmarks: brain accumulation of β -amyloid (A), tau (T), and/or neurodegeneration (N). Typically, low CSF β -amyloid 1-42 (A β_{42}) indicates A+, and conversely high phosphorylated tau 181 (p-tau₁₈₁) and total tau (t-tau) in CSF can indicate T+ and N+, respectively. More recently, neurofilament light chain (NfL) has been used as a marker of N status, instead of t-tau. Indeed, accumulating evidence shows that serum NfL may be a useful marker of disease progression and degeneration in PD^{8–11}. While the the ATN framework is starting to be applied in LBD^{12,13}, its prognostic utility has not been thoroughly evaluated in PD. In PD, NfL is untested in the context of ATN, and it is unknown if there will be added prognostic value when combined with AD CSF

biomarkers. There is also evidence that CSF p-tau₁₈₁ and t-tau are less informative in PD, showing an altered profile and low levels¹⁴ that may reduce their sensitivity for classifying AD^{15} . Thus, CSF $A\beta_{42}$ alone may be sufficient to detect evidence of AD pathology in PD¹⁶ and to predict clinical decline in PD^{17,18}. The added utility of CSF p-tau, as well as serum NfL, when combined with CSF $A\beta_{42}$ (*i.e.*, ATN) is undetermined, and head-to-head comparisons of AD biomarker strategies to predict clinical cognitive decline in PD are lacking.

This study of the Parkinson's Progression Marker Initiative (PPMI) cohort had two goals: to track the potentially unique AD biofluid trajectories in PD, and to test how biomarker strategies may be applied to identify biologically-relevant subgroups and improve clinical prognosis in PD. In part 1, we described longitudinal CSF (A β_{42} , p-tau₁₈₁, t-tau) and serum NfL biofluid trajectories from baseline to year 5 in PD, compared to clinicallynormal Controls without motor or cognitive impairments. We also tested if biomarker trajectories in PD differed by baseline CSF A β_{42} (*i.e.*, evidence of β -amyloid accumulation) or baseline CSF α -synuclein (α -syn) (*i.e.*, potential evidence of α -syn accumulation). In part 2, we compared two biomarker strategies to predict future clinical outcomes in PD: 1) CSF A β_{42} as a marker of A status and 2) a modified ATN strategy (ATN_{PD}) using a lower PD-established cutpoint for T status¹⁹ and serum NfL as the marker of N. Ancillary analyses evaluated traditional ATN (CSF A β_{42} , p-tau₁₈₁, and t-tau) to test if results were cutpoint or analyte dependent. We tested the hypothesis that ATN_{PD} incorporating T and N status would improve prediction of clinical outcomes in PD; alternatively A status alone may be sufficient for prognosis in early PD. We also predicted that AD biomarker strategies would specifically associate with declines in cognition, language, and postural stability in PD, but not with other motor and autonomic functioning, in line with previous literature^{3–6}.

2. Materials and methods

PPMI is a longitudinal, observational study, with data collection from approximately 50 international sites. Data were selected on September 7, 2021 from the PPMI database^{20,21}. All procedures were performed with prior approval from ethical standards committees at each participating institution and with informed consent from all study participants. CSF and clinical data were obtained annually at baseline (year 0) and follow-up visits (years 1 – 5); serum NfL was obtained at years 0, 1, 2, 3, and 5. A subset of these data was previously reported¹⁷.

2.1 Participants

Inclusion criteria were participants diagnosed with PD who, at baseline, were drug-naïve and had CSF A β_{42} , p-tau₁₈₁, t-tau, α -syn, and serum NfL measurements (n=364); in addition they were within 2 years of PD diagnosis, not diagnosed with dementia, and sporadic (without *LRRK2*, *GBA*, or *SNCA* mutations). Controls were included as a reference group who had a normal clinical diagnosis (n=168). Exclusion criteria were prodromal PD (conversion to PD during the follow-up period), parkinsonism but without evidence of dopaminergic deficit syndrome, or a diagnosis change to multiple system atrophy (MSA) or corticobasal syndrome. Of those followed at baseline, 284 PD (78%) and 141 Controls (84%) were still followed by year 5.

2.2 CSF and serum assays

Biofluid collection and handling were completed according to standard operating procedures at each institution (see biologics manual: <ppmi.info.org>). CSF α -syn and serum NfL were analyzed as previously described^{8,22}. For measurement of CSF A β_{42} , p-

tau₁₈₁, and t-tau, CSF samples were shipped from the PPMI Biorepository Core Laboratories to the Penn Biomarker Research Laboratory using Elecsys® electrochemiluminescence immunoassays on the cobas e 601 analysis platform (Roche Diagnostics)^{23,24}.

Biofluid data were from two batches (2016, 2021). The 2021 batch was 68 analytical runs done in a total of 34 days: 2/22/2021 through 4/16/2021. Single reagent lots were used throughout the study for each analyte.

A total of 2733 CSF samples were processed in this project, including 2463 PPMI patient samples, 134 PPMI pools, and 136 internal UPenn pool controls. Among the 2463 patient samples, there were 75 "bridging" samples previously analyzed in the 2017 batch. These 75 retests were planned for the purpose of evaluating the assay lot-to-lot performance.

The "bridging" samples were mixed-in with the regular study samples during the first 10 days of analyses (first 20 runs). Regression equations were obtained using the Passing-Bablok method²⁵, using the regression equation: $[2021 result] = \beta_0 + \beta_1 [2017 result]$.

Summarized are the model intercepts (β_0) and 95% confidence intervals (CI) for each analyte: A β_{42} =8.04 (95%CI=-169.9 – 153.4); t-tau=-3.29 (95%CI=-14.76 – 8.23); p-tau₁₈₁=0.36 (-0.18 – 1.01)]. The summarized model slopes (β_1) are A β_{42} =1.15 (95%CI=0.99 – 1.40); t-tau=1.10 (95%CI=0.94 – 1.10); p-tau₁₈₁=0.93 (95%CI=0.88 – 0.97). Intercepts and slopes for t-tau and p-tau₁₈₁ met criteria for acceptable lot-to-lot performance: intercept <50% lower than the lowest reportable value, and slope between 0.90–1.10. To achieve complete comparability of the A β_{42} assay, we re-scaled the results of all CSF samples to the values measured in 2017, using the regression equation for A β_{42} .

Precision performance was evaluated using 4 CSF pools, each included in the 68 analytical runs. For A β_{42} %CV values ranged from 3.8 to 5.8%; t-tau %CV from 2.9 to 3.3% and for p-tau₁₈₁ %CV from 2.8 to 5.2%.

2.2.1 ATN framework and interpretation

A status. CSF A β_{42} determined A status for all strategies. To account for CSF A β_{42} preanalytical factors that affect cutoff application in the PPMI dataset^{23,26}, a threshold of 683 was calculated¹⁹: CSF A $\beta_{42} \leq 683$ pg/mL indicated A+ and A $\beta_{42} > 683$ pg/mL indicated Afor all strategies (A Status, modified ATN_{PD}, and traditional ATN).

Modified ATN_{PD} . As above, CSF A $\beta_{42} \le 683$ pg/mL indicated A+. For T status, CSF ptau₁₈₁ \ge 13 pg/mL indicated T+ based on a PD-established cutpoint¹⁹. Serum NfL determined N status. Because no established thresholds were available for serum NfL, the threshold was determined from this PD sample based on the 75% quartile for NfL at baseline; thus NfL ≥ 19.05 pg/mL indicated N+.

Traditional ATN. Traditional ATN applied thresholds established in AD. As above, CSF $A\beta_{42} \le 683 \text{ pg/mL}$ indicated A+. For T status, CSF p-tau₁₈₁ $\ge 24 \text{ pg/mL}$ indicated T+²⁷. For N status, CSF t-tau ≥ 266 indicated N+²⁷.

 ATN_{PD} and ATN Interpretation. Despite different biomarkers and thresholds, both ATN_{PD} and ATN used the same schema to interpret statuses⁷. Combining biomarkers classified individuals along a spectrum of AD: normal (A-T-N-), early Alzheimer's change (A+T-N-), AD (A+T+N-, A+T+N+), suspected non-AD pathology (SNAP) (A-T+N-, A-T-N+, A-T+N+), and concomitant Alzheimer's change and SNAP (A+T-N+). In sum, both A+ and T+ are required to meet a diagnosis of AD, while A- in the presence of T+ and/or N+ is considered SNAP.

2.3 Demographics, Clinical, and Genetic Data

Demographic variables were age at baseline visit, age at symptom onset, disease duration (years from onset to test), education (years), and gender. The PPMI genetics core analyzed blood samples for apolipoprotein E (APOE) genotype²⁸ and mutations associated with PD risk (*e.g.*, *LRRK2*, *GBA*, *SNCA*)²⁹.

Clinical variables were obtained for each visit (baseline and follow-ups). Metrics of cognitive function were Montreal Cognitive Assessment (MoCA; lower scores indicate worse global function), Hopkins Verbal Learning Test (HVLT) recognition discrimination score (lower scores indicate worse episodic memory), Symbol Digit Modalities Test (SDMT; lower scores indicate worse processing speed), Benton Judgment of Line Orientation score (JOLO; lower scores indicate worse visuospatial functioning), Semantic Fluency (lower scores indicate worse verbal generativity and semantic knowledge), Letter Number Sequencing (lower scores indicate worse executive functioning), and the Movement Disorders Society modified Unified Parkinson's disease rating scale (MDS-UPDRS) part I item 1.1 Cognitive Impairment (MDS-UPDRS I Cog; higher scores indicate more severe cognitive impairment)³⁰. Metrics of motor functioning were Hoehn & Yahr³¹, MDS-UPDRS part III total motor score off levodopa treatment (MDS-UPDRS III Motor)³⁰, tremor, and postural instability/gait dysfunction (PIGD) (higher scores indicate more severe impairment). Tremor and PIGD were calculated averages derived from MDS-UPDRS part II and III relevant items³². The metric for nonmotor/cognitive autonomic functioning was the Scales for Outcomes in Parkinson's Disease-Autonomic Dysfunction (SCOPA-AUT; higher scores indicate more severe impairment)³³.

2.4 Statistical Analyses

Biofluid, demographic, and clinical variables had a non-normal distribution. Mann–Whitney–Wilcoxon tests performed pairwise comparisons for continuous variables, and chi-square tests compared frequency distributions of categorical variables. In models, CSF and serum biomarkers were log-transformed, and β estimates and 95% confidence intervals (95% CI) are reported. Because distributions varied for clinical variables, clinical variables were rank-transformed to perform non-parametric analyses³⁴. Missing data were dropped listwise from models. Statistical tests were performed with a significance threshold of α =0.05. Nominal and false detection rate (FDR)-adjusted *p*-values are reported. Analyses were conducted using R version 4.1.2 (2021-11-01) statistical software.

2.4.1 Part 1: Biofluid Trajectories in PD and Controls

Linear mixed effects models (LMEMs) tested how each analyte changed over time (Equation 1); an interaction term between visit year (0-5) and group tested for divergence in analyte trajectories between PD and Controls. Models covaried for age at baseline, gender, APOE ε 4 (dominant model: 0 *vs*. 1/2 ε 4 alleles), with a random intercept for individual (γ) and residual error (ε).

[1] Analyte =
$$\beta_0 + \beta_1 Group \times \beta_2 Year + \beta_3 Age + \beta_4 Gender + \beta_5 APOE\varepsilon 4 + \gamma + \varepsilon$$

In PD, we tested how evidence of β -amyloid at baseline related to longitudinal trajectories in p-tau₁₈₁, t-tau, and NfL; LMEMs tested for an interaction between time and baseline CSF A β_{42} (Equation 2). Models covaried for age at baseline, gender, and APOE ϵ 4 carrier status.

[2] Analyte = $\beta_0 + \beta_1 A \beta_{Baseline} \times \beta_2 Year + \beta_3 Age + \beta_4 Gender + \beta_5 APOE \varepsilon 4 + \gamma + \varepsilon$

Longitudinal CSF α -syn trajectories in this PPMI cohort were previously reported²². In addition to baseline CSF A β_{42} , we also tested how baseline CSF α -syn interacted with longitudinal trajectories in CSF A β_{42} , p-tau₁₈₁, t-tau, and serum NfL (Equation 3).

[3] Analyte = $\beta_0 + \beta_1 \alpha$ -syn_{Baseline} × β_2 Year + β_3 Age + β_4 Gender + β_5 APOE ε 4 + γ + ε

We examined distributions of 2 biomarker strategies to classify PD over time: modified ATN_{PD} and A status. Chi-square tests examined if classifications changed from year 0 to year 5. We included traditional ATN as a reference.

2.4.3 Part 2: Prediction of clinical outcomes by biomarker strategy We compared ATN_{PD} to A status to predict longitudinal clinical outcomes. We tested if declines in clinical outcomes were associated with co-occurring AD in PD, as defined by ATN_{PD} and by A status. LMEMs tested for an interaction between ATN_{AD} (AD *vs*. other statuses) and year (Equation 4); we also tested for an interaction between A status (A+ *vs*. A-) and year (Equation 5). Models covaried for education and gender, as these variables are known to influence cognitive performance.

[4] Clinical Outcome = $\beta_0 + \beta_1 ATN_{PD} \times \beta_2 Year + \beta_3 Education + \beta_4 Gender + \gamma + \varepsilon$

[5] Clinical Outcome = $\beta_0 + \beta_1 A Status \times \beta_2 Year + \beta_3 E ducation + \beta_4 Gender + \gamma + \varepsilon$

To determine added utility of CSF p-tau₁₈₁ and serum NfL when combined with CSF $A\beta_{42}$, analyses of variance (ANOVA) compared model fitness between nested models: A status interacting with time (Equation 5) compared to AT (Equation 6), and AT compared to ATN (Equation 7). Metrics of fitness were Akaike information criterion (AIC) and log likelihood; chi-square and *p*-values indicated if the model with more parameters significantly reduced variance.

[6] Clinical Outcome = $\beta_0 + \beta_1 AStatus \times \beta_2 Year + \beta_3 TStatus \times \beta_2 Year + \beta_4 Education + \beta_5 Gender + \gamma + \varepsilon$

[7] Clinical Outcome = $\beta_0 + \beta_1 AStatus \times \beta_2 Year + \beta_3 TStatus \times \beta_2 Year + \beta_4 NStatus \times$

 β_2 *Year* + β_5 *Education* + β_6 *Gender* + γ + ε

2.5 Data Availability

Data contained in this study were obtained from the PPMI database and are available

upon request at www.ppmi-info.org.

2.6 Standard Protocol Approvals, Registrations, and Patient Consents

Informed consent was obtained from all participants or legal representatives under guidelines established and approved by the ethical standards committees at each participating institution.

3. Results

Table 1 summarizes characteristics of PD and Control cohorts at baseline. Supplemental Figure 1 illustrates pairwise correlations of analytes at baseline across PD and Controls; CSF A β_{42} , p-tau₁₈₁, t-tau, and α -syn were positively correlated with each other in both groups (all *p*<0.0001). Serum NfL was not correlated with either CSF A β_{42} or CSF α -syn at baseline (all *p*>0.31).

Missing values at baseline. APOE ɛ4 was missing for 34 PD and 14 Controls. PD were missing data for HVLT (n=1), Semantic Fluency (n=1), Letter Number Sequencing (n=1), JOLO (n=1), and SCOPA-AUT (n=8).

Longitudinal Retainment. By year 5, 284 (78% of baseline) PD had been assessed for MDS-UPDRS I Cog, PIGD, and Tremor; 283 (79% of baseline) had completed SCOPA-AUT; 282 (78% of baseline) PD had completed HVLT, Letter Number Sequencing, MoCA, Semantic Fluency, and SDMT; 280 (77% of baseline) had completed JOLO; 209 (57% of baseline) had completed Hoehn & Yahr; and 207 (57% of baseline) had completed MDS-UPDRS III Motor.

3.1 Part 1: Longitudinal biofluid trajectories

First, LMEMs tested longitudinal trajectories of each analyte and for a group by time interaction (Figure 1). PD showed greater increases in serum NfL over time than Controls (β =0.035, 95%CI=0.022 – 0.048, *p*=2.5e-07), and applying FDR-correction (FDR-*p*=9.8e-07). Greater declines in CSF A β_{42} in PD compared to Controls (β =-0.01, 95%CI=-0.02 – -2e-04, *p*=0.046) did not survive FDR-correction (FDR-*p*=0.18). There was no significant interaction of group with longitudinal trajectories of p-tau₁₈₁ (*p*=0.30) or t-tau (*p*=0.24).

Testing main effect of diagnosis group, PD had overall lower CSF p-tau₁₈₁ (β =-0.16, 95%CI=-0.23 – -0.092, *p*=5.5e-06) and t-tau (β =-0.13, 95%CI=-0.19 – -0.065, *p*=1e-04) relative to controls, and survived FDR-correction (p-tau₁₈₁ FDR-*p*=2.2e-05; t-tau FDR-*p*=4.0e-04). Lower CSF A β_{42} in PD (β =-0.091, 95%CI=-0.16 – -0.018, *p*=0.015) did not survive FDR-correction (FDR-*p*=0.061), and group did not show a main effect for serum NfL (β =0.06, 95%CI=-0.0069 – 0.13, *p*=0.080). Full models are reported in Supplementary Table 1.

Within PD, we next tested how longitudinal changes of p-tau₁₈₁, t-tau and NfL related to baseline CSF A β_{42} (Figure 2); LMEMs tested for a time by baseline CSF A β_{42} (continuous variable) interation. In PD, higher baseline A β_{42} was associated with greater declines in p-tau₁₈₁ (β =-0.026, 95%CI=-0.035 – -0.017, *p*=2.5e-08) and t-tau over time (β =-0.025, 95%CI=-0.035 – -0.014, *p*=1.2e-05); both p-tau₁₈₁ (FDR-*p*=7.5e-08) and t-tau (FDR-*p*=3.6e-05) survived FDR-correction. Baseline CSF A β_{42} did not affect the trajectory of NfL (*p*=0.73). Full models are reported in Supplementary Table 2.

Additionally, we tested how longitudinal trajectories of CSF A β_{42} , p-tau₁₈₁, t-tau and serum NfL related to baseline CSF α -syn. PD biofluid trajectories were not affected by baseline CSF α -syn (all *p*>0.16; data not shown).

3.1.1 PD biomarker classifications over time

Figure 3 shows how each biomarker strategy classified PD patients at baseline and in year 5. For A status, 116 (32%) PD patients were A+ at baseline. Under modified ATN_{PD}, 32 (9%) PD patients were classified as AD (A+T+N±) at baseline. Under traditional ATN, 7 (2%) PD patients were classified as AD (A+T+N±) at baseline. Chi-square tests tested if classifications changed over time. Both A status (χ^2 =7, *p*=0.012) and modified ATN_{PD} classifications differed from baseline to year 5 (χ^2 =13, *p*=0.012); traditional ATN classifications did not significantly differ (χ^2 =7.1, *p*=0.067).

3.2 Part 2: Biomarker strategies to predict longitudinal clinical outcomes

3.2.1 Longitudinal cognitive outcomes

Next, we tested how modified ATN_{PD} at baseline predicted longitudinal cognitive decline, and how ATN_{PD} performed compared to A status (Figure 4). Full models, as well as traditional ATN results, are reported in the Supplementary Tables 3-5.

*ATN*_{PD}. Testing how AD[A+T+N±] (n=32) *vs*. all other statuses (n=332) at baseline predicts cognitive decline, LMEMs showed a significant interaction between ATN_{PD} and time with all cognitive tests before FDR-correction. A+T+N± PD had more severe declines for MoCA (β =-73, 95%CI=-110 – -37, *p*=6.4e-05; FDR-*p*=0.00077), SDMT (β =-60, 95%CI=-88 – -32, *p*=3.7e-05; FDR-*p*=0.00044), Semantic Fluency (β =-73, 95%CI=-100 – -46, *p*=1.1e-07; FDR-*p*=1.3e-06), and MDS-UPDRS I Cog than all other ATN_{PD} statuses (β =65, 95%CI=30 – 100, *p*=3e-04; FDR-*p*=0.0036). Greater declines for A+T+N± PD in HVLT (β =-58, 95%CI=-100 – -15, *p*=0.0079), JOLO (β =-53, 95%CI=-92 – -13, *p*=0.0089), and Letter Number Sequencing (β =-39, 95%CI=-71 – -7.2, *p*=0.016)

did not survive FDR-correction (HVLT FDR-*p*=0.095; JOLO FDR-*p*=0.11; Letter Number Sequencing FDR-*p*=0.20).

A Status. We repeated models using A Status to test if A status alone was sufficient to predict cognitive decline. Testing A+ (n=116) *vs*. A- (n=248) at baseline, LMEMs tested for an interaction between A status and time. A+ PD had lower MoCA (β =-31, 95% CI=-51 - -11, *p*=0.0026; FDR-*p*=0.032) and more severe MDS-UPDRS I Cog than A- PD (β =33, 95% CI=13 - 54, *p*=0.0012; FDR-*p*=0.014). Worse JOLO (β =-24, 95% CI=-46 - -1.5, *p*=0.037) and Letter Number Sequencing (β =-19, 95% CI=-37 - -0.22, *p*=0.047) for A+ PD did not survive FDR-correction (JOLO FDR-*p*=0.44; Letter Number Sequencing FDR-*p*=0.57). The interaction was not significant for HVLT (*p*=0.20), SDMT (β =-15, 95% CI=-31 - 1.7, *p*=0.08)0, or Semantic Fluency (β =-15, 95% CI=-31 - 0.63, *p*=0.060).

3.2.2 Longitudinal motor and autonomic outcomes

We tested how modified ATN_{PD} at baseline predicted longitudinal motor/autonomic decline, and how ATN_{PD} performed compared to A status (Figure 5). Full models for motor and autonomic functioning, as well as traditional ATN results, are reported in the Supplementary Tables 6-8.

ATN_{PD}. We tested how AD[A+T+N±] (n=32) *vs*. all other statuses (n=332) at baseline predicts longitudinal motor and autonomic decline. LMEMs showed a significant interaction between ATN_{PD} and time with for PIGD (β =69, 95%CI=29 – 110, *p*=0.00069); this interaction survived FDR correction (FDR-*p*=0.0083). There was not a significant interaction for SCOPA-AUT (β =27, 95%CI=-1.8 – 56, *p*=0.066), UPDRS III Motor (*p*=0.42), Tremor (*p*=0.95), or Hoehn & Yahr (*p*=0.78).

A Status. We tested how A+ (n=116) *vs.* A- (n=248) at baseline predicted longitudinal motor and autonomic decline. The interaction between A status and time for PIGD (β =29,

95%CI=6.4 – 52, p=0.012) did not survive FDR correction (FDR-p=0.15). There was no interaction for SCOPA-AUT (β =15, 95%CI=-1.9 – 32, p=0.083), UPDRS III Motor (p=0.24), Tremor (p=0.11), or Hoehn & Yahr (p=0.81).

3.2.3 Model comparison: modified ATN_{PD} vs. A status

To determine if ATN_{PD} improved predictions of clinical decline, ANOVAs compared model fitness of A status *vs.* AT_{PD} , and AT_{PD} *vs.* ATN_{PD} (Table 2). Results showed improved model fit for ATN_{PD} for all cognitive outcomes except JOLO, with most metrics seeing additional improvement for both T and N statuses. In addition, there was improved model fit when N status was included for PIGD.

For traditional ATN (Supplemental Table 9), T status improved model fit for MoCA, HVLT, SDMT, Semantic Fluency, and MDS-UPDRS I Cog (all FDR-p<0.029). Results were not significant for JOLO (FDR-p=0.083), SCOPA-AUT (FDR-p=0.083), Letter Number Sequencing or any motor test (all FDR-p>0.16). Addition of N status using CSF t-tau did not improve any of the models (Letter Number Sequencing FDR-p=0.083; all other FDR-p>0.1).

4. Discussion

Here we tested ATN_{PD} – combining CSF A β_{42} , p-tau₁₈₁, and serum NfL – as a modified strategy to detect co-occurring AD in PD. Previous work shows that CSF A β_{42} predicts clinical outcomes in PD^{17,18,35,36}, while CSF p-tau₁₈₁ and t-tau appear to have less utility in PD^{18,37}. This may be in part because CSF p-tau₁₈₁ and t-tau levels are consistently low in PD¹⁷, which can make it difficult to determine clinically relevant levels of p-tau₁₈₁. Here we tested if T status had added clinical utility to CSF A β_{42} , despite low levels of CSF p-tau₁₈₁ in PD. We also tested serum NfL as a marker of N, since NfL may be

clinically useful in $PD^{8-11,38}$, although few have tested the contribution of NfL in combination with AD biomarkers in PD.

Our data show that ATN_{PD} classified 32 PD (9%) as AD positive (A+T+N±) at baseline. While small, this subset had strong associations with later cognitive decline; $A+T+N\pm$ PD had more severe decline for all seven cognitive tests measured, with four significant after FDR-correction (MoCA, SDMT, Semantic Fluency, and MDS-UPDRS I Cog). These findings suggest an added predictive value of T status to A+ status in PD. While metrics of motor and autonomic functioning all significantly declined with time, only PIGD showed greater declines associated with $A+T+N\pm$. PIGD has been previously associated with CSF $A\beta_{42}^{39,40}$. This specificity of A+T+N± with decline in cognitive function, but not motor or autonomic functioning, indicates that ATN_{PD} classifications are not simply capturing overall disease severity. A status alone was associated with some metrics of cognitive decline, still model comparisons showed that fitness significantly improved with ATN_{PD} and the addition of T status, and again with N status. Figure 5 highlights the divergent trajectories of A+T+N± ("AD") from A+T-N-("Amyloid"), further supporting that T and N statuses have added value for clinical prognosis (note also, A+T-N+, but with small sample size n=9). Importantly, we used a PD-specific cutpoint for p-tau₁₈₁ (\geq 13 pg/mL)¹⁹, however results showed that p-tau₁₈₁ also had prognostic utility when using the AD-derived cutpoint (≥ 24 pg/mL)²⁷ (traditional ATN); thus our findings are not solely driven by the PD-specific cut point used to define ATN_{PD}. In sum, CSF A β_{42} , p-tau₁₈₁, and serum NfL used in combination in ATN_{PD} may be highly informative for predicting clinical outcomes in PD.

Our examination of analyte trajectories confirms a biomarker profile in PD that is distinct from canonical AD, although the mechanism for this difference is unknown. Consistent with β -amyloid pathology (*i.e.*, A+ status), CSF A β_{42} was lower in PD than controls, and decreased over time. However, both CSF p-tau₁₈₁ and t-tau were lower overall in PD than controls. This is in contrast to AD, where CSF p-tau₁₈₁ and t-tau increase in association with tau pathology and neurodegeneration^{41,42}. Another distinction of these data is that CSF A β_{42} , p-tau₁₈₁ and t-tau were all positively correlated. Again, this pattern is in contrast to AD studies which instead show an inverse association between CSF $A\beta_{42}$ and p-tau₁₈₁ and t-tau (low A β_{42} and high p-tau₁₈₁/t-tau)⁴³. We tested how biomarker trajectories might differ by baseline CSF A β_{42} , hypothesizing that CSF p-tau₁₈₁ and t-tau may show greater increases in PD with low baseline CSF $A\beta_{42}$ (A+). Overall CSF ptau₁₈₁ and t-tau were lower in PD with low CSF A β_{42} , and longitudinal models showed that CSF p-tau₁₈₁ and t-tau significantly decreased over time in PD with higher CSF A β_{42} levels (A-). It is possible that early PD is marked by initial declines in CSF tau, and future studies are needed to test if CSF tau rises in late-stage PD. The low tau levels observed here are in agreement with autopsy studies showing that tau pathology is less abundant in PD and other LBD than AD⁴⁴. Further, CSF p-tau₁₈₁ and t-tau may have an inverse association with α -synuclein pathology¹⁵. Still, the mechanism for low CSF levels in PD is unknown and our analyses showed no interaction between baseline CSF α -syn and AD biomarkers. Given this altered CSF profile in PD, we developed a modified ATN_{PD} strategy, which applied a lower, PD-established threshold for p-tau₁₈₁¹⁹. We observed that CSF p-tau₁₈₁ is informative for predicting cognitive decline in PD, and models demonstrated improved fit when combining CSF p-tau_{181} with A β_{42} . Moreover,

our results were robust and not cutpoint dependent: traditional ATN with a higher ptau₁₈₁ cutpoint also predicted cognitive decline, albeit for a smaller proportion of PD (n=7; 2%). This is corroborated by other studies that show improved predictive accuracy for cognitive decline in PD when combining CSF A β_{42} and p-tau₁₈₁⁴⁵. In sum, our results indicate that CSF p-tau₁₈₁ has added utility when combined with CSF A β_{42} .

In addition to threshold adjustments for CSF p-tau₁₈₁, ATN_{PD} incorporated serum NfL as a marker of N. NfL is a structural component of myelinated axons, and concentrations of NfL increase in the blood and CSF following axonal injury⁴⁶. The application of NfL in PD and in the ATN_{PD} framework has several advantages. First, unlike CSF t-tau, we show that serum NfL is not correlated with CSF A β_{42} or p-tau₁₈₁, and is invariant to other indicators of AD pathology including APOE E4; thus, serum NfL is an orthogonal marker of N with increased utility compared to t-tau. Our results showed improved model fit for 7 of 12 clinical outcomes with inclusion of N status using serum NfL under ATN_{PD}. In contrast, traditional ATN using t-tau as a marker of N status did not improve model fit. CSF t-tau's lack of added utility is in part because it is highly correlated with p-tau₁₈₁, both in this PD cohort (rho=0.97; Supplementary Figure 1) and in AD samples⁴⁷; thus ttau is somewhat redundant with p-tau₁₈₁. Second, there is substantial evidence that NfL is a more sensitive marker of N for non-AD neurodegenerative diseases than t-tau⁴⁸, and strongly associates with disease progression, motor and cognitive severity in $PD^{38,49,50}$. In this study, we also find that NfL levels significantly increased with time, and this increase was greater in PD than Controls. The utility of serum NfL in PD was further supported by improved model fit, not just for cognitive outcomes, but also for autonomic (SCOPA-AUT) and some motor outcomes (PIGD, Hoehn & Yahr), although only PIGD survived

FDR-correction. Our data indicate that serum NfL does not associate with AD biomarkers in PD, and thus the predictive advantage of serum NfL in PD may possibly be due to a closer association with α -synuclein pathological processes, however this potential association needs to be confirmed.

There are several caveats to consider when interpreting our findings here. Foremost, while our results firmly show that ATN_{PD} is clinically relevant, we lack autopsy data to test external validity of ATN_{PD} to identify co-occurring AD compared to other biomarker strategies. This limitation highlights the need to test PD-specific biomarker cutpoints using autopsy data. Even so, detailed, systematic, longitudinal data in PD are rare, and because PPMI is an international multi-center study, it is more robust against selection and collection bias. Thus we find strong evidence that the combination of CSF A β_{42} , ptau₁₈₁, and serum NfL are useful for predictive cognitive decline in PD. Second, there is minimal overall cognitive impairment in PPMI during this time interval of follow up. Likewise, only 32 PD met an ATN_{PD} definition of AD (A+T+N±) at baseline. While our findings indicate that these $A+T+N\pm$ individuals had a divergent cognitive trajectory, it will be important to validate these findings in a larger sample of $A+T+N\pm$ PD, beyond the 5 years in this study. Future studies should test the prognostic accuracy of ATN_{PD} categories to predict which PD individuals will develop overt dementia, or to distinguish fast vs. slow progressors. It will also be important to determine the optimal level of classification detail that best predicts clinical outcomes in PD in future work (e.g., A+SNAP [A+T-N+] vs AD [A+T+N \pm]) since we were limited in numbers for some subgroups of ATN classification (A+SNAP n=9). Third, we did not test alternative strategies combining CSF A β_{42} and p-tau₁₈₁, such as the p-tau₁₈₁/A β_{42} , which has been

shown to contribute to predictions of cognitive decline in PD⁴⁵. Fourth, we did not test application in other LBD, such as dementia with lewy bodies (DLB) and PD with dementia (PDD), and it will be important to test if ATN_{PD} broadly applies to α synucleinopathies. Finally, we lacked an accurate marker of α -synuclein pathology to incorporate in ATN_{PD}. Previous work shows poor prognosis of motor function in PD using available CSF α -syn²². Recent seeding assay technology has made possible accurate stratification using CSF α -synuclein, and future longitudinal studies in prodromal and early PD should test the trajectories of ATN_{PD} + α -synuclein to understand the temporal dynamics and interactions between biomarkers.

In sum, this paper shows that an ATN_{PD} strategy which combines AD CSF biomarkers with serum NfL can classify early PD into biological subgroups that show clinically meaningful differences within 5 years. This study also highlights the need to study AD co-pathology and biomarkers in a PD-specific context, including continued tracking of AD biomarkers in across disease stage in PD and the establishment of PD-specific cutpoints for AD biomarkers using autopsy-confirmed data.

Acknowledgement

This work is supported by funding from the National Institute of Aging (P30-AG072979). KAQC is supported by the Alzheimer's Association (AARF-D-619473, AARF-D-619473-RAPID). PPMI is sponsored by the Michael J. Fox Foundation for Parkinson's Research (MJFF) and is co-funded by MJFF, Abbvie, Allergan, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali, Eli Lilly & Co., F. Hoffman-La Roche, Ltd., GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Merck, Meso- Scale, Piramal, Prevail Therapeutics, Pfizer, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Berily, and Voyager Therapeutics. This work was supported by a grant from MJFF.

Author Contributions

KC, DI, TT, ER, JP, AC, DI, and LS all contributed to the methodology and design of the study. KC, DI, CC, JK, TS, TF, AT, CT, KK, BM, DG, SH, DW, AS, KM, KP, and LS contributed to the acquisition and analysis of data. KC contributed to drafting the text or preparing the figures.

Potential Conflicts of Interest

LMS received support in an investigator-initiated grant from Roche for all immunoassay reagents and instrumentation for the analyses in CSF samples of A β_{42} , t-tau and ptau₁₈₁. Authors report no conflicts of interest relevant to this study.

References

1. Baba M, Nakajo S, Tu P-H, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. The American journal of pathology. American Society for Investigative Pathology; 1998;152:879.

2. Irwin DJ, Lleó A, Xie SX, et al. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Annals of neurology. Wiley Online Library; 2017;82:247–258.

3. Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. Journal of Neural Transmission [online serial]. 2002;109:329–339. Accessed at: *https://doi.org/10.1007/s007020200027*.

4. Shellikeri S, Cho S, Cousins KAQ, et al. Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias. Parkinsonism & Related Disorders [online serial]. Epub 2022. Accessed at:

https://www.sciencedirect.com/science/article/pii/S1353802022002486.

5. Howard E, Irwin DJ, Rascovsky K, et al. Cognitive Profile and Markers of Alzheimer Disease–Type Pathology in Patients With Lewy Body Dementias. Neurology [online serial]. 2021;96:e1855 LP–e1864. Accessed at:

http://n.neurology.org/content/96/14/e1855.abstract.

6. Lee Y, Jeong SH, Park M, et al. Effects of Alzheimer's genetic risk scores and CSF biomarkers in de novo Parkinson's Disease. npj Parkinson's Disease [online serial]. 2022;8:57. Accessed at: *https://doi.org/10.1038/s41531-022-00317-8*.

7. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia [online serial]. Elsevier Inc.; 2018;14:535–562. Accessed at: *https://doi.org/10.1016/j.jalz.2018.02.018*.

8. Mollenhauer B, Dakna M, Kruse N, et al. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. Movement Disorders [online serial]. John Wiley & Sons, Ltd; 2020;35:1999–2008. Accessed at: *https://doi.org/10.1002/mds.28206*.

9. Sampedro F, Pérez-González R, Martínez-Horta S, Marín-Lahoz J, Pagonabarraga J, Kulisevsky J. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease. Parkinsonism & Related Disorders [online serial]. 2020;74:43–49. Accessed at:

https://www.sciencedirect.com/science/article/pii/S1353802020301048.

10. Pötter-Nerger M, Dutke J, Lezius S, et al. Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study. Journal of Neural Transmission [online serial]. 2022;129:295–300. Accessed at: *https://doi.org/10.1007/s00702-022-02464-x*.

11. Ygland Rödström E, Mattsson-Carlgren N, Janelidze S, Hansson O, Puschmann A. Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes. Journal of Parkinson's Disease. IOS Press; 2022;12:571–584.

12. Bellomo G, Paolini Paoletti F, Chipi E, et al. A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies. Diagnostics [online serial]. Multidisciplinary Digital Publishing Institute; 2020;10:1015. Accessed at: *https://www.mdpi.com/*2075-4418/10/12/1015.

13. Ferreira D, Przybelski SA, Lesnick TG, et al. β -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology. AAN Enterprises; 2020;95:e3257–e3268.

14. Mollenhauer B, Parnetti L, Rektorova I, et al. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Journal of Neurochemistry [online serial]. John Wiley & Sons, Ltd; 2016;139:290–317. Accessed at: *https://doi.org/10.1111/jnc.13390*.

15. Cousins KAQ, Arezoumandan S, Shellikeri S, et al. CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α -Synuclein Pathology. Neurology [online serial]. Epub 2022 Aug.:10.1212/WNL.000000000201202. Accessed at: *http://n.neurology.org/content/early/2022/08/30/WNL.000000000201202.abstract.*

16. Vromen EM, Boer SCM de, Teunissen CE, et al. Biomarker A+T-: is this Alzheimer's disease or not? A combined CSF and pathology study. Brain [online serial]. Epub 2022 May.:awac158. Accessed at: *https://doi.org/10.1093/brain/awac158*.

17. Irwin DJ, Fedler J, Coffey CS, et al. *Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease*. Annals of Neurology. 2020;88:574–587.

18. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology [online serial]. 2010;75:1055 LP–1061. Accessed at: *http://n.neurology.org/content/75/12/1055.abstract*.

19. Weinshel S, Irwin DJ, Zhang P, et al. *Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease*. Journal of Parkinson's Disease. IOS Press; 2022;12:1155–1167.

20. Marek K, Jennings D, Lasch S, et al. The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology [online serial]. 2011;95:629–635. Accessed at: *https://www.sciencedirect.com/science/article/pii/S0301008211001651*.

21. Marek K, Chowdhury S, Siderowf A, et al. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology [online serial]. John Wiley & Sons, Ltd; 2018;5:1460–1477. Accessed at: *https://doi.org/10.1002/acn3.644*.

22. Mollenhauer B, Caspell \Box Garcia CJ, Coffey CS, et al. Longitudinal analyses of cerebrospinal fluid $\alpha \Box$ Synuclein in prodromal and early Parkinson's disease. Movement disorders. Wiley Online Library; 2019;34:1354–1364.

23. Shaw LM, Waligorska T, Fields L, et al. Derivation of cutoffs for the Elecsys amyloid β (1–42) assay in Alzheimer's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring [online serial]. John Wiley & Sons, Ltd; 2018;10:698–705. Accessed at: *https://doi.org/10.1016/j.dadm.2018.07.002*.

24. Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer's disease concord with amyloid- β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's & Dementia [online serial]. 2018;14:1470–1481. Accessed at:

https://www.sciencedirect.com/science/article/pii/S1552526018300293.

25. Manuilova E, Schuetzenmeister A, Model F. MCR: method comparison regression. R package version. 2014;1.

26. Stewart T, Shi M, Mehrotra A, et al. Impact of pre-analytical differences on biomarkers in the ADNI and PPMI studies: implications in the era of classifying disease based on biomarkers. Journal of Alzheimer's Disease. IOS Press; 2019;69:263–276.

27. Blennow K, Shaw LM, Stomrud E, et al. Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys A β (1–42), pTau and tTau CSF immunoassays. Scientific reports. Nature Publishing Group; 2019;9:1–11.

28. Kang J-H, Mollenhauer B, Coffey CS, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathologica [online serial]. 2016;131:935–949. Accessed at: *https://doi.org/10.1007/s00401-016-1552-2*.

29. Simuni T, Uribe L, Cho HR, et al. *Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.* The Lancet Neurology. Elsevier; 2020;19:71–80.

30. Goetz CG, Tilley BC, Shaftman SR, et al. *Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results.* Movement Disorders. 2008;23:2129–2170.

31. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations the Movement Disorder Society Task Force on rating scales for Parkinson's disease. Movement disorders. Wiley Online Library; 2004;19:1020–1028.

32. Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K. *How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?* Parkinsonism & Related Disorders. Elsevier; 2016;28:62–67.

33. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA AUT. Movement disorders: official journal of the Movement Disorder Society. Wiley Online Library; 2004;19:1306–1312.

34. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. The American Statistician. Taylor & Francis; 1981;35:124–129.

35. Compta Y, Pereira JB, Ríos J, et al. Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study. Parkinsonism & Related Disorders [online serial]. 2013;19:717–724. Accessed at:

https://www.sciencedirect.com/science/article/pii/S1353802013001259.

36. Alves G, Brønnick K, Aarsland D, et al. Journal of Neurology, Neurosurgery & Psychiatry [online serial]. 2010;81:1080–1086. Accessed at:

http://jnnp.bmj.com/content/81/10/1080.abstract.

37. Kwon EH, Tennagels S, Gold R, Gerwert K, Beyer L, Tönges L. Update on CSF Biomarkers in Parkinson's Disease. Biomolecules [online serial]. Multidisciplinary Digital Publishing Institute; 2022;12:329. Accessed at: *https://www.mdpi.com/2218-273X/12/2/329*.

38. Aamodt WW, Waligorska T, Shen J, et al. Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Movement Disorders. Wiley Online Library; 2021;36:2945–2950.

39. Alves G, Pedersen KF, Bloem BR, et al. Journal of Neurology, Neurosurgery & Psychiatry [online serial]. 2013;84:537 LP–543. Accessed at: *http://jnnp.bmj.com/content/84/5/537.abstract*.

40. Kang J-H, Irwin DJ, Chen-Plotkin AS, et al. Association of Cerebrospinal Fluid β -Amyloid 1-42, T-tau, P-tau181, and α -Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurology [online serial]. 2013;70:1277–1287. Accessed at: *https://doi.org/10.1001/jamaneurol.2013.3861*.

41. Tapiola T, Alafuzoff I, Herukka S-K, et al. Cerebrospinal fluid β -amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Archives of neurology. American Medical Association; 2009;66:382–389.

42. Zetterberg H. Tau in biofluids–relation to pathology, imaging and clinical features. Neuropathology and applied neurobiology. Wiley Online Library; 2017;43:194–199.

43. Kac PR, Gonzalez-Ortiz F, Simrén J, et al. Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. Alzheimer's Research & Therapy [online serial]. 2022;14:65. Accessed at: *https://doi.org/10.1186/s13195-022-01011-w*.

44. Coughlin D, Xie SX, Liang M, et al. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. Annals of Neurology [online serial]. John Wiley & Sons, Ltd; 2019;85:259–271. Accessed at: *https://doi.org/10.1002/ana.25392*.

45. Harvey J, Reijnders RA, Cavill R, et al. Machine learning-based prediction of cognitive outcomes in de novo Parkinson's disease. npj Parkinson's Disease 2022 8:1 [online serial]. Nature Publishing Group; 2022;8:1–11. Accessed at: *https://www.nature.com/articles/s41531-022-00409-5*.

46. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology. Nature Publishing Group; 2018;14:577–589.

47. Khoonsari PE, Shevchenko G, Herman S, et al. Improved differential diagnosis of Alzheimer's disease by integrating ELISA and mass spectrometry-based cerebrospinal fluid biomarkers. Journal of Alzheimer's Disease. IOS Press; 2019;67:639–651.

48. Cousins KAQ, Phillips JS, Irwin DJ, et al. ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. Alzheimer's & Dementia. Wiley Online Library; 2021;17:822–830.

49. Lin C-H, Li C-H, Yang K-C, et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology. AAN Enterprises; 2019;93:e1104–e1111.

50. Huang Y, Huang C, Zhang Q, Shen T, Sun J. Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity. BMC Neurology [online serial]. 2022;22:39. Accessed at: *https://doi.org/10.1186/s12883-022-02558-9*.

Figure Legends

Figure 1. Analyte trajectories over time. Least squares regression lines and standard error are plotted for PD (blue) and Controls (grey) for each analyte by visit year (0-5).

Figure 2. Changes in analytes over time by baseline CSF A β_{42} . Least squares regression lines with standard error show analyte concentrations over time for PD (left panels) and Controls (right panels). For visualization, baseline CSF A β_{42} was dichotomized; color represents low (red; <685) or high (blue; >685) CSF A β_{42} at baseline.

Figure 3. Classifications of PD across biomarker strategies. Classification proportions of PD over time by traditional ATN, A Status, and modified ATN_{PD} . Sample sizes for each classification are reported. Color indicates ATN and ATN_{PD} interpretation: Normal (white; A-T-N-), Amyloid (coral; A+T-N-), AD (A+T+N-, A+T+N+), A+SNAP (purple; A+T-N+), and SNAP (blue; A-T+N-, A-T-N+, A-T+N+). For A Status, interpretation is either A- (white) or A+ (coral). Sample sizes for each classification are reported.

Figure 4. Modified ATN_{PD} vs. A status associations with cognitive decline. Least squares regression lines and standard error intervals plot performance over time for each cognitive metric. Color indicates classification by A status (left panels: A- = grey; A+ = coral) and ATN_{PD} (right panels: Normal = grey; Amyloid = coral; AD = red; A+SNAP = purple; SNAP = blue). Asterisks indicate nominal p<0.05.

Figure 5. Modified ATN_{PD} vs. A status associations with motor and autonomic decline. Least squares regression lines and standard error intervals plot performance over time for each motor/autonomic metric. Color indicates classification by A status (left panels: A- = grey; A+ = coral) and ATN_{PD} (right panels: Normal = grey; Amyloid = coral; AD = red; A+SNAP = purple; SNAP = blue). Asterisks indicate nominal p<0.05.


Demographic Characteristics	PD	Control	p	
n	364	168		
Age at Baseline (years)	62.4 [55.0, 69.3]	61.8 [55.5, 69.2]	0.399	
Age at Onset (years)	60.6 [53.1, 67.4]			
Disease duration (months)	4.2 [2.5, 8.0]			
MoCA	27.5 [26.0, 29.0]	28.0 [27.0, 29.0]	< 0.001	
Hoehn & Yahr	2.0 [1.0, 2.0]	0.0 [0.0, 0.0]	< 0.001	
MDS-UPDRS Total	31.0 [23.0, 40.0]	3.0 [1.0, 7.0]	< 0.001	
Education (years)	16.0 [14.0, 18.0]	16.0 [14.0, 18.0]	0.080	
Gender = Female $(\%)$	133 (36.5%)	61 (36.3%)	1.000	
APOE ε4 (%)			0.943	
0	242 (73.3%)	113 (73.4%)		
1	81 (24.5%)	37 (24.0%)		
2	7 (2.1%)	4 (2.6%)		

Tables


Table 1: Demographic, genetic, and clinical characteristics of PD and Controls. For continuous variables, median and interquartile range (IQR) are reported; Wilcoxon tests performed group comparisons. For categorical variables, count (percentage [%]) are provided; chi-square tests performed frequency comparisons. *p*-values are reported for group comparisons.


	npar	AIC	logLik	χ2	Df	р	FDR-p
HVLT.model = A	8	29,794	-14,889				
HVLT.model = AT_PD	10	29,790	-14,885	7.7	2	0.021	0.043
HVLT.model = ATN_PD	12	29,782	-14,879	11.9	2	0.003	0.01
JOLO.model = A	8	29,473	-14,728				
JOLO.model = AT_PD	10	29,476	-14,728	0.4	2	0.819	0.819
JOLO.model = ATN_PD	12	29,474	-14,725	6.5	2	0.038	0.066
Letter Number.model = A	8	29,085	-14,534				
Letter Number.model = AT_PD	10	29,079	-14,530	9.4	2	0.009	0.024
Letter Number.model = ATN_PD	12	29,074	-14,525	9.0	2	0.011	0.026
MoCA.model = A	8	29,358	-14,671				
MoCA.model = AT_PD	10	29,356	-14,668	6.0	2	0.049	0.073
MoCA.model = ATN_PD	12	29,351	-14,663	9.5	2	0.009	0.024
SDMT.model = A	8	28,729	-14,356				
SDMT.model = AT_PD	10	28,722	-14,351	10.7	2	0.005	0.017
SDMT.model = ATN_PD	12	28,711	-14,343	15.5	2	< 0.001	0.004
Semantic Fluency.model = A	8	28,573	-14,278				
Semantic Fluency model = AT_PD	10	28,561	-14,270	16.1	2	< 0.001	0.004
Semantic Fluency.model = ATN_PD	12	28,551	-14,264	13.8	2	0.001	0.006
UPDRS I cog.model = A	8	29,291	-14,637				
UPDRS I cog.model = AT_PD	10	29,271	-14,625	24.4	2	< 0.001	< 0.001
UPDRS I cog.model = ATN_PD	12	29,262	-14,619	12.5	2	0.002	0.009
Hoehn & Yahr.model = A	8	22,880	-11,432				
Hoehn & Yahr.model = AT_PD	10	22,883	-11,431	1.9	2	0.396	0.413
Hoehn & Yahr.model = ATN_PD	12	22,880	-11,428	6.7	2	0.035	0.064
PIGD.model = A	8	29,842	-14,913				
PIGD.model = AT_PD	10	29,840	-14,910	5.8	2	0.054	0.077
PIGD.model = ATN_PD	12	29,836	-14,906	8.7	2	0.013	0.029
SCOPA-AUT.model = A	8	28,656	-14,320				
SCOPA-AUT.model = AT_PD	10	28,655	-14,318	4.5	2	0.106	0.134
SCOPA-AUT.model = ATN_PD	12	28,653	-14,315	6.1	2	0.048	0.073
Tremor.model = A	8	29,746	-14,865				
Tremor.model = AT_PD	10	29,748	-14,864	2.3	2	0.318	0.347
Tremor.model = ATN_PD	12	29,749	-14,863	3.1	2	0.217	0.248
UPDRS III Motor.model = A	8	23,056	-11,520				
UPDRS III Motor.model = AT_PD	10	23,055	-11,517	4.9	2	0.088	0.117
UPDRS III Motor.model = ATN_PD	12	23,055	-11,516	3.7	2	0.154	0.185


Table 2: Comparison of nested models (A vs. AT_{PD} vs. ATN_{PD}) for prediction of clinical outcomes. Summary of ANOVAs comparing model fitness for modified ATN_{PD} . Columns report number of parameters per model (npar), AIC, log liklihood (logLik), chi-square (χ^2), degrees of freedom (Df), *p*-values, and FDR-*p*.




















A+

Amyloid

A+SNAP

medRxiv preprint doi: https://doi.org/10.1101/2023.04.21.23288930; this version posted April 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted mediate a transpose by display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

